Overview
- Neko Health announced the $700 million Series C on Wednesday, July 15, 2026, with Lightspeed Venture Partners and O.G. Venture Partners listed as lead investors.
- The round drew a long list of high‑profile individual backers including Mark Zuckerberg, Priscilla Chan, Tim Ferriss, Maria Sharapova, and will.i.am, and unnamed reporting has suggested a roughly $7 billion post‑round valuation that the company has not confirmed.
- The company says the capital will fund an immediate U.S. push beginning with a New York clinic whose waitlist is open, though Neko has not disclosed U.S. pricing or how it will work with insurers.
- Neko emphasizes vertical integration of proprietary hardware and software and recently rolled out next‑generation devices (Derma‑2, Echo‑2, Spectrum‑2) plus wearable data integration to speed automated full‑body scans and same‑day bloodwork results.
- Reporters note persistent questions about independent clinical validation of Neko’s outcome claims, the equity implications of a largely cash‑pay model, and whether the capital intensity of in‑house manufacturing can scale against rivals such as Prenuvo and Function Health.